Intra-Cellular Therapies, Inc.
NOVEL USES
Last updated:
Abstract:
The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.
Status:
Application
Type:
Utility
Filling date:
2 Jun 2021
Issue date:
2 Dec 2021